Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioCardia, Inc.BCDA;BCDAW · Entity 7752 | Chief Medical Officer | November 02, 2020 | November 03, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioCardia, Inc.
Report date November 02, 2020 · Filed November 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,088 |
Reported balance
After 2020-11-02 transaction · row 1
1 source rowRow 1 · 2020-11-02 · Sale · Disposed 8,435 · Balance 12,088 F1: This transaction was executed in multiple trades ranging from $2.00 to $2.02 per share. The price reported above reflects the weighted average per share sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades ranging from $2.00 to $2.02 per share. The price reported above reflects the weighted average per share sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2020 Filed Nov 3, 2020 23:06 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | SaleCommon Stock | 8,435 | $2.01 | $16,954.35 |
DisclosureSEC source: 0001437749-20-022418 · rdgdoc.xml · nonDerivative · entry 1 Duckers Eric · CIK 0001686154 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,088 F1 · price: This transaction was executed in multiple trades ranging from $2.00 to $2.02 per share. The price reported above reflects the weighted average per share sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares sold at each separate price. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 01:15 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | Tax withholdingCommon Stock | 7,154 | $2.40 | $17,169.60 |
DisclosureSEC source: 0001437749-20-014424 · rdgdoc.xml · nonDerivative · entry 1 Duckers Eric · CIK 0001686154 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,523 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested on June 30, 2020 and does not represent a sale by the Reporting Person. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 23:19 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantStock Option (right to buy) · Derivative | 25,500 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001437749-20-008734 · rdgdoc.xml · derivative · entry 2 Duckers Eric · CIK 0001686154 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 25,500 shares Expires 2030-04-24 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 1/48th of the shares on May 24, 2020 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 23:19 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-008734 · rdgdoc.xml · nonDerivative · entry 1 Duckers Eric · CIK 0001686154 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,677 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vest on June 30, 2020. Read SEC document |
| March 11, 2020 Filed Mar 28, 2020 01:57 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | Tax withholdingCommon Stock | 1,205 | $3.60 | $4,338.00 |
DisclosureSEC source: 0001437749-20-006393 · rdgdoc.xml · nonDerivative · entry 2 Duckers Eric · CIK 0001686154 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,177 F3 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: This share amount reflects the number of shares beneficially owned as of the filing date of this Form 4. Read SEC document |
| August 27, 2019 Filed Mar 28, 2020 01:57 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 2,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-006393 · rdgdoc.xml · nonDerivative · entry 1 Duckers Eric · CIK 0001686154 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,382 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vest on January 29, 2020. F2 · balance_after: This share amount reflects the number of shares beneficially owned as of the filing date of this Form 4. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:41 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseWarrant (right to buy) · Derivative | 8,435 | Not disclosed Strike: $6.30 | Not disclosed |
DisclosureSEC source: 0001437749-19-016066 · rdgdoc.xml · derivative · entry 4 Duckers Eric · CIK 0001686154 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,435 Underlying: Common Stock · 8,435 shares Expires 2024-08-06 F1 · shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · price: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · derivative.underlying_shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:41 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | ConversionConvertible promissory note · Derivative | Not disclosed | $0.00 Strike: $3.00 | $25,000.00 |
DisclosureSEC source: 0001437749-19-016066 · rdgdoc.xml · derivative · entry 3 Duckers Eric · CIK 0001686154 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 8,435 shares Expires 2020-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · reported_value: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · derivative.underlying_shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:41 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | ConversionCommon Stock | 8,435 | $3.00 | $25,305.00 |
DisclosureSEC source: 0001437749-19-016066 · rdgdoc.xml · nonDerivative · entry 1 Duckers Eric · CIK 0001686154 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. Read SEC document |
| July 05, 2019 Filed Aug 8, 2019 20:41 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseConvertible promissory note · Derivative | Not disclosed | $25,000.00 Strike: $8.00 | $25,000.00 |
DisclosureSEC source: 0001437749-19-016066 · rdgdoc.xml · derivative · entry 2 Duckers Eric · CIK 0001686154 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 3,125 shares Expires 2020-01-05 F1 · derivative.exercise_price: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · reported_value: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · derivative.underlying_shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. Read SEC document |
| February 01, 2018 Filed Mar 22, 2018 18:24 UTC | BioCardia, Inc. BCDA · Entity 7752 | GrantStock Option (right to buy) · Derivative | 167,880 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001437749-18-005230 · rdgdoc.xml · derivative · entry 1 Duckers Eric · CIK 0001686154 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,880 Underlying: Common stock · 167,880 shares Expires 2028-02-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 1/48th of the shares on March 1, 2018 and each monthly anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.